# Biocad

Source: https://onco.cc/companies/biocad/  
OnCo record `biocad` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Biocad is a Russian biotechnology company that makes biosimilars of rituximab, bevacizumab and trastuzumab and developed prolgolimab, the first anti-PD-1 antibody approved in Russia, now tested with its anti-CTLA-4 partner nurulimab in melanoma.

## Summary

Biocad, based in St Petersburg, is Russia's largest biotechnology company by its own account, with biosimilars of rituximab, bevacizumab and trastuzumab that supply much of the Russian market and an in-house immuno-oncology pipeline. Its anti-PD-1 antibody prolgolimab (BCD-100, brand name Forteca) received Russian approval for melanoma in 2020 and is in phase 3 trials as a fixed combination with the anti-CTLA-4 antibody nurulimab (BCD-217) in unresectable and resectable melanoma. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: BIOCAD
- Tags: ctgov-sponsor
- HQ: St Petersburg
- Type: biotech
- Website: https://biocad.ru/

## Sources

- Official website: https://biocad.ru/
- ClinicalTrials.gov: trials led by Biocad: https://clinicaltrials.gov/search?lead=Biocad

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [BCD-100](https://onco.cc/drugs/bcd-100/), [BCD-217](https://onco.cc/drugs/bcd-217/)
- institutions: [N. N. Blokhin National Medical Research Center of Oncology](https://onco.cc/institutions/blokhin-cancer-center/), [N. N. Petrov National Medical Research Centre of Oncology](https://onco.cc/institutions/petrov-institute/)
- trials: [A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma](https://onco.cc/trials/nct05732805/), [A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma](https://onco.cc/trials/nct05751928/), [A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)](https://onco.cc/trials/nct07742215/), [An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct06668792/), [BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct07108309/), [Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer](https://onco.cc/trials/nct05802225/), [Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin](https://onco.cc/trials/nct06640530/)
- key papers: [DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer](https://onco.cc/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/), [MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma](https://onco.cc/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/)

---
JSON: https://onco.cc/api/v1/entities/biocad.json